Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications.
Recently, an increasing number of patients with liver metastases from colorectal cancer have received chemotherapy before hepatectomy. However, the effect of chemotherapy on postoperative short-term outcome is not well defined.



We retrospectively investigated the postoperative complications of 439 patients who underwent hepatectomy for colorectal liver metastases in our division from 2005 to 2014. Patients were classified into two groups according to the presence (Cx; 84 patients) or absence (NCx; 355 patients) of preoperative chemotherapy. Univariate and multivariate analyses were conducted to determine the predictive factors for postoperative complications.



There was neither mortality nor liver failure after surgery. There was no significant difference in the frequency of postoperative complications between Groups Cx and NCx [29 vs 26 % for all complications; both 6 % for bile leakage that required therapeutic intervention; and 2 vs 3 % for Clavien-Dindo (CD) Grade ≥ IIIa, respectively]. In Group Cx, morbidity rates were similar among patients with different chemotherapy regimens. Chemotherapy-related factors (administration of bevacizumab, oxaliplatin or irinotecan, duration of chemotherapy >150 days, and timing of hepatectomy) were not significantly associated with clinically relevant bile leakage and CD ≥ IIIa in multivariate analysis.



Even after combination chemotherapy including targeted therapy, hepatectomy for colorectal liver metastases can be performed safely without increasing morbidity or mortality, if the patients fulfill the conventional criteria for surgery.
Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kengo
K
Fukuoka
Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. sanara@ncc.go.jp.
Satoshi
S
Nara
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Yoshitaka
Y
Honma
Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yoji
Y
Kishi
Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Minoru
M
Esaki
Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kazuaki
K
Shimada
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D011183:Postoperative Complications / Q000209:etiology; D012189:Retrospective Studies; D016896:Treatment Outcome
Int J Cancer. 2015 Mar 1;136(5):E359-86
25220842
Ann Surg. 2008 Jan;247(1):118-24
18156931
Arch Surg. 1999 Sep;134(9):984-92
10487594
J Surg Oncol. 2005 Sep 1;91(3):173-80
16118771
Surgery. 2011 May;149(5):713-24
21236455
Ann Surg. 2014 Mar;259(3):543-8
23732261
HPB (Oxford). 2010 Feb;12(1):43-9
20495644
Ann Surg. 2006 Jan;243(1):8-9
16371729
Ann Surg Oncol. 2010 Oct;17 (10 ):2747-55
20425145
J Clin Oncol. 2006 Nov 1;24(31):4983-90
17075116
J Clin Oncol. 2008 Nov 10;26(32):5254-60
18854565
Ann Surg Oncol. 2009 Jan;16(1):35-41
18987915
Ann Surg. 2006 Jan;243(1):1-7
16371728
Hepatology. 2005 Jun;41(6):1313-21
15915461
Int J Clin Oncol. 2015 Apr;20(2):207-39
25782566
Br J Cancer. 2007 Apr 10;96(7):1037-42
17353923
Lancet. 2008 Mar 22;371(9617):1007-16
18358928
Ann Surg Oncol. 2010 Nov;17(11):2870-6
20567921
Oncologist. 2009 Nov;14 (11):1095-105
19880627
Ann Surg Oncol. 2006 Oct;13(10):1271-80
16955381
J Clin Oncol. 2006 May 1;24(13):2065-72
16648507
Ann Oncol. 2004 Mar;15(3):460-6
14998849
Surgery. 2011 May;149(5):680-8
21316725
J Am Coll Surg. 2013 Jan;216(1):41-9
23041049
J Clin Oncol. 2008 Apr 10;26(11):1830-5
18398148
Anticancer Res. 2015 Apr;35(4):2255-61
25862887
Ann Surg. 2013 Mar;257(3):377-82
22895397
World J Surg. 2010 Jan;34(1):92-100
19838754
Ann Surg. 2010 Nov;252(5):774-87
21037433
J Am Coll Surg. 2008 Jan;206(1):96-106
18155574
Br J Surg. 1999 Mar;86(3):332-7
10201774
Surgery. 1990 May;107(5):521-7
2333592
Ann Surg. 2004 Aug;240(2):205-13
15273542
Histopathology. 2010 Mar;56(4):430-9
20459550
Ann Surg. 2009 Mar;249(3):420-5
19247029
Cancer. 2007 Dec 15;110(12):2761-7
17960603